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Fenofibrate prevents iron induced activation of canonical
Wnt/β-catenin and oxidative stress signaling in the retina
Ashok Mandala1, Austin Armstrong1, Becky Girresch2, Jiyao Zhu2, Aruna Chilakala1, Sanmathi Chavalmane3, Kapil Chaudhary4,
Pratim Biswas3, Judith Ogilvie2 and Jaya P. Gnana-Prakasam 1,5✉
Accumulating evidence strongly implicates iron in the pathogenesis of aging and disease. Iron levels have been found to increase
with age in both the human and mouse retinas. We and others have shown that retinal diseases such as age-related macular
degeneration and diabetic retinopathy are associated with disrupted iron homeostasis, resulting in retinal iron accumulation. In
addition, hereditary disorders due to mutation in one of the iron regulatory genes lead to age dependent retinal iron overload and
degeneration. However, our knowledge on whether iron toxicity contributes to the retinopathy is limited. Recently, we reported
that iron accumulation is associated with the upregulation of retinal and renal renin–angiotensin system (RAS). Evidences indicate
that multiple genes/components of the RAS are targets of Wnt/β-catenin signaling. Interestingly, aberrant activation of Wnt/
β-catenin signaling is observed in several degenerative diseases. In the present study, we explored whether iron accumulation
regulates canonical Wnt signaling in the retina. We found that in vitro and in vivo iron treatment resulted in the upregulation of
Wnt/β-catenin signaling and its downstream target genes including renin–angiotensin system in the retina. We confirmed further
that iron activates canonical Wnt signaling in the retina using TOPFlash T-cell factor/lymphoid enhancer factor promoter assay and
Axin2-LacZ reporter mouse. The presence of an iron chelator or an antioxidant reversed the iron-mediated upregulation of Wnt/
β-catenin signaling in retinal pigment epithelial (RPE) cells. In addition, treatment of RPE cells with peroxisome proliferator-activated
receptor (PPAR) α-agonist fenofibrate prevented iron-induced activation of oxidative stress and Wnt/β-catenin signaling by
chelating the iron. The role of fenofibrate, an FDA-approved drug for hyperlipidemia, as an iron chelator has potentially significant
therapeutic impact on iron associated degenerative diseases.
npj Aging and Mechanisms of Disease            (2020) 6:12 ; https://doi.org/10.1038/s41514-020-00050-7
INTRODUCTION
Iron plays a vital role in the retina with many iron containing
proteins involved in the phototransduction cascade1. A stringent
balance during iron uptake, transport, storage and utilization is
required to maintain iron homeostasis2. However, excess iron
promotes the generation of reactive oxygen species (ROS)
through Fenton reaction causing molecular and cellular dysfunc-
tions3. Age-related increases in iron levels have been found in the
human and mouse retinas4,5. In addition, disrupted iron home-
ostasis in hereditary and acquired diseases such as aceruloplas-
minemia6, hemochromatosis7,8, Friedreich’s ataxia9, diabetic
retinopathy (DR)10, age-related macular degeneration (AMD)11,
glaucoma12, ocular siderosis13, multiple blood transfusions14, and
excess dietary iron supplementation15 have been reported to
cause retinal iron accumulation and degeneration.
Our recent study showed that retinal iron accumulation
exacerbates cell death through oxidative stress, inflammasome
activation, and enhanced renin–angiotensin system (RAS) activ-
ity10. RAS plays an important role in regulating vasoconstriction
and electrolyte balance. Angiotensin II (Ang II) is the primary
molecule of RAS produced as a result of cleavage of angiotensino-
gen (AGT) by renin and angiotensin-converting enzyme (ACE)
sequentially. Ang II then binds to Ang II type 1 (AT1) and Ang II
type 2 (AT2) receptors wielding diverse pathophysiological effects.
Activation of retinal RAS due to concurrent upregulation of
multiple RAS genes is associated with many ocular diseases
including DR, AMD, uveitis, and glaucoma16. Recent studies
established that all components of the RAS, including AGT, renin,
ACE, AT1, and AT2 are downstream targets of Wingless-related
integration site (Wnt)/β-catenin signaling17. However, it is not
known whether iron can regulate retinal Wnt/β-catenin signaling.
The Wnt signaling is a group of signal transduction pathways with
diverse role during embryonic growth and development. In the
canonical Wnt pathway, secreted Wnt ligands bind to the Wnt
receptor Frizzled (Fzd) and co-receptor low-density lipoprotein
receptor-related protein (LRP5/6) leading to its phosphorylation
and activation18. This leads to inactivation of the “destruction
complex” consisting of GSK-3β (glycogen synthase kinase-3β),
Axin, and APC (adenomatous polyposis coli). This prevents the
proteasomal degradation of β-catenin and promotes its accumu-
lation and nuclear translocation. In the nucleus, β-catenin
associates with T-cell factor (TCF) and regulates the expression
of many target genes, including VEGF (vascular endothelial growth
factor). Altered Wnt signaling has been reported as a contributing
factor in various ocular disorders and malignancies19–21. Wnt
activation may contribute to the angiogenesis, inflammation, and
fibrosis22. In addition, the Wnt pathway affects cell adhesion
through the binding of β-catenin and E-cadherin23. Wnt signaling
has antagonistic pleiotropic effects, because they are quintessen-
tial earlier in life but deleterious later in life19. Downregulation of
Wnt/β-catenin signaling and RAS blockade have been shown to
protect against aging24. However, current therapy with RAS
inhibitors have limited efficacy because of compensatory
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upregulation of renin expression25 necessitating the need for a
new strategy to simultaneously target multiple RAS genes for a
more effective treatment.
Peroxisome proliferator-activated receptors (PPARs) are nuclear
receptors that play an important role as transcription factors in
regulating the expression of genes involved in the lipid
metabolism26. PPARα, PPARβ/δ, and PPARγ are the three isoforms,
of which PPARα is crucial in the regulation of fatty acid oxidation,
inflammation and angiogenesis26. Fenofibrate, a PPARα agonist,
has been found to be effective in the amelioration of micro-
vascular complications of diabetes in the FIELD and ACCORD
trials27–29. Also, fenofibrate has been shown to potently block the
activation of Wnt signaling in the kidney by destabilizing LRP6
mediated through inhibiting the renal ROS production30. In the
present study, we determined if iron accumulation regulates
canonical Wnt signaling in the retina and the therapeutic role of
PPARα agonist fenofibrate in preventing iron-induced Wnt
signaling.
RESULTS
Iron induces canonical Wnt/β-catenin signaling in the retinal
pigment epithelial cells
To investigate whether retinal iron accumulation during aging and
degenerative diseases modulates canonical Wnt/β-catenin signal-
ing, a human retinal pigment epithelial (RPE) cell line ARPE19 was
treated with different concentrations of ferric ammonium citrate
(FAC) for 24 h. FAC treatment increased the expression of total and
non-phospho (active) β-catenin levels in a dose dependent
manner (Fig. 1a). The expression levels of p-GSK-3β (Serine 9),
GSK-3β, and LRP6 were upregulated by FAC (Fig. 1b). Further, FAC
treatment increased the nuclear translocation of β-catenin as the
active β-catenin levels in the nuclear fraction increased with FAC
treatment but there was no change in the expression levels in the
cytosolic fraction (Fig. 1c). mRNA expression of β-catenin down-
stream target genes Axin2, cMYC, CCND (cyclin D), and VEGF were
significantly upregulated in FAC-treated human RPE cells in a dose
dependent manner (Fig. 1d). Similarly, ARPE19 cells transfected
with TopFlash reporter, increased the luciferase reporter activity in
FAC-treated cells compared to the untreated cells (Fig. 1e). These
results indicate that retinal iron overload inhibits GSK-3β and
upregulates LRP6, thereby activating β-catenin signaling in the
human RPE cells.
Iron activates retinal canonical Wnt/β-catenin signaling in vivo
A Wnt signaling reporter mouse Axin2lacZ /+ was used to confirm if
iron regulates retinal Wnt signaling in vivo. The Axin2 gene is a
known target of the canonical Wnt signaling and Axin2LacZ mice
were generated by a stable knock in of LacZ in frame with the
start codon of the endogenous Axin2 to visually localize the Wnt
signaling activation31,32. X-Gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) staining of retinal sections from intravitreal
holo-transferrin (iron)-treated eyes of Axin2lacZ/+ mouse showed
upregulated Wnt signaling activity, mainly in the ganglion cell
layer, inner nuclear layer, and, to a lesser extent, in the outer
nuclear layer and RPE compared to the apo-transferrin (control)-
Fig. 1 Iron induces canonical Wnt signaling in the retinal pigment epithelial cells. a Total and active β-catenin (non-phospho) protein levels
were estimated by western blot in ARPE19 cells treated with different concentrations of FAC for 24 h. β-Actin was used as a loading control.
b Protein expression of GSK-3β, p-GSK-3β, LRP6, and p-LRP6 were determined by western blotting. β-Actin was used as a loading control.
c Expression of active β-catenin in cytosolic and nuclear fractions isolated from ARPE19 cells treated with FAC for 24 h. β-Actin and HDAC1
were used as loading controls for cytosolic and nuclear fractions respectively. In a–c, blots cropped from different parts of the same gel or
from different gels are separated by white space. d mRNA expression of Wnt downstream target genes Axin2, cMYC, CCND, and VEGF in the
cells treated with different concentrations of FAC for 24 h. e Renilla luciferase activity in the TCF/LEF Reporter transfected cells. LiCl and Wnt3a
were used as a positive control. Data presented as mean ± SE of three independent experiments; *p < 0.05; **p < 0.001.
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treated eyes (Fig. 2a). To determine whether iron alters β-catenin
protein expression in vivo, wild-type (WT) mice were administered
with holo-transferrin (iron) or apo-transferrin (control) intravitreally
and the retinal β-catenin levels were compared. We first confirmed
that holo-transferrin treated retina had iron accumulation by
checking the protein levels of H- (heavy chain) and L- (light chain)
ferritin, an indirect indicator of intracellular iron levels (Fig. 2b).
Holo-transferrin treated retina exhibited increased expression of
active β-catenin compared to the apo-transferrin treated retina
(Fig. 2c). To check if systemic iron overload can cross the blood-
retinal barrier and regulate retinal Wnt signaling, mice were
treated with iron-dextran intraperitoneally. The expression of H-
and L-ferritin was higher in the retina of mice treated with iron
dextran than the phosphate-buffered saline (PBS)-treated group
(Fig. 2d). Further, iron dextran treated mice showed upregulation
of active β-catenin in the retina (Fig. 2e). These results imply that
both systemic and localized iron overload activates canonical Wnt/
β-catenin signaling in the retina.
Iron accumulation and enhanced Wnt signaling in the rd1 mouse
model of Retinitis Pigmentosa
To check whether iron accumulation is associated with increase in
Wnt signaling during pathological conditions, we used rd1 mouse
model of Retinitis Pigmentosa (RP). RP is the leading cause of
inherited retinal blindness in the United States and is character-
ized by progressive degeneration of rod photoreceptors with no
effective treatments currently available33. Oxidative stress has
been shown to play an important role and the use of antioxidants
reduced rod cell death in the retinal degeneration rd1 and rd10
mouse models of RP33. Importantly, the zinc–desferrioxamine
complex has been shown to attenuate retinal degeneration in
rd10 mouse model of RP by chelating the labile iron34. However,
there is no literature on the iron status in rd1 or rd10 mouse
models of RP. Here we show that H- and L-ferritin levels are higher
in the rd1 mouse retina at postnatal P16 by which time more than
half of the rod photoreceptors have degenerated (Fig. 3a). Binding
of iron regulatory proteins to iron response element in the 3′-
untranslated region of TfR1 regulates the expression of TfR1
resulting in TfR1 levels to be inversely proportional to the cellular
iron status2. Thus, a decrease in TfR1 levels indicates iron
accumulation in the retinas of rd1 mice (Fig. 3a). Similarly, active
β-catenin and downstream target genes were significantly
upregulated in the retinas of rd1 mice compared to WT mice at
P16 (Fig. 3b, c). Labile iron staining using FeRhoNox-1 fluorescent
imaging probe confirmed increase in Fe2+ iron accumulation in
not only the RPE and outer nuclear layer containing the
photoreceptors but also distributed throughout the nuclear and
plexiform layers of the rd1 mice retina at P16 (Fig. 3d). 4-
hydroxynonenal (4-HNE), a lipid peroxidation product, is upregu-
lated during iron-mediated oxidative stress35. Similar to the labile
iron staining, retinal sections stained for 4-HNE revealed robust
increase throughout the rd1 retinas compared to WT retinas at
P16 (Fig. 3e). In postnatal P6 and P10 mice, we found a similar
increase in ferritin and active β-catenin protein levels in the rd1
mice retinas compared to WT retinas (Supplementary Fig. 1a, b),
indicating that rd1 mouse model of RP has iron accumulation and
associated increase in retinal Wnt signaling even before the
photoreceptor degeneration starts at P10, thereby implying a
contributory role for iron in the progression of RP.
Fig. 2 Iron activates retinal canonical Wnt/β-catenin signaling in vivo. a Representative images of retinal sections from Axin2LacZ/+ mice
treated with apo- and holo-transferrin (Tfn), and stained for X-gal. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer;
RPE, retinal pigment epithelium. Heavy (H-) chain ferritin, light (L-) chain ferritin and active β-catenin protein levels were determined by
immunoblotting after (b, c) intravitreal injection of apo- and holo-transferrin (Tfn) in the mice and (d, e) intraperitoneal injection of iron
dextran for 8 weeks. α-Tubulin or GAPDH was used as an internal control. In b–e, blots cropped from different parts of the same gel or from
different gels are separated by white space. Data presented as mean ± SE; n= 4–8 mice per group; *p < 0.05; ***p < 0.0001.
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Iron-induced activation of Wnt signaling is mediated by oxidative
stress
Oxidative stress has been reported to play an important role in the
Wnt3a ligand-induced canonical Wnt/β-catenin signaling in
endothelial cells36. RPE cells treated with FAC in vitro and mice
treated with iron dextran in vivo upregulated the expression of Src
collagen homolog (p66 Shc1) (Fig. 4a, b), an indicator of redox
imbalance that plays a vital role in Wnt3a-induced oxidative stress
and canonical Wnt signaling activation36,37. To investigate
whether the iron-mediated oxidative stress is responsible for the
activation of Wnt signaling in the retina, cells were treated with
antioxidant N-acetyl cysteine (NAC, 5 mM) or iron chelator
deferiprone (DFP, 100 µM) in the presence of FAC. Treatment
with NAC or DFP significantly reduced the FAC-induced upregula-
tion of LRP6 and active β-catenin (Fig. 4c). Further, western
blotting in the nuclear and cytosolic fraction demonstrates that
DFP treatment significantly reduced the translocation of active
β-catenin to the nucleus (Fig. 4d). In summary, these results
establish that iron induces ROS generation and increases LRP6,
activating the Wnt signaling in the retina.
PPARα agonist fenofibrate prevents iron-induced Wnt signaling in
ARPE19 cells
Fenofibrate, a PPARα agonist has recently been reported to
suppress Wnt3a induced β-catenin signaling in renal cells30. To
investigate whether the iron-induced activation of canonical Wnt
signaling in the retina is abrogated by fenofibrate, ARPE19 cells
were treated with fenofibrate in the presence of 100 µg/mL FAC
for 24 h. Treatment with fenofibrate significantly reversed the
upregulation of FAC-induced active β-catenin and total β-catenin
levels (Fig. 5a). Further, fenofibrate prevented the FAC-mediated
upregulation of cMYC, LRP6, and p-GSK-3β (S9) expression
(Fig. 5b), and significantly reduced the nuclear translocation of
β-catenin in ARPE19 cells (Fig. 5c). Similarly, fenofibrate prevented
the FAC-induced upregulation of active β-catenin expression
significantly in the primary RPE cells (Fig. 5d). In addition,
fenofibrate abrogated the FAC-mediated upregulation of p66
Shc1, an indicator of redox imbalance, in primary RPE cells
(Fig. 5e). Taken together, these results indicate that FAC-induced
dysregulation of canonical Wnt signaling in the retina could be
prevented by fenofibrate.
Fenofibrate is an iron chelator
The anti-cancer activity of new compounds with iron chelation
capability has recently been demonstrated to be antagonizing the
Wnt signaling activation38,39. Our experiments with DFP also
indicate that iron chelation is an effective strategy to inhibit Wnt
signaling. Next, we determined whether fenofibrate prevents the
activation of Wnt signaling by reducing the intracellular iron
levels. ARPE19 cells treated with fenofibrate normalized the
expression of TfR1 and ferritin levels altered by FAC treatment
(Fig. 6a), indicating that fenofibrate reduces intracellular iron
accumulation. In addition, we found that fenofibrate reversed
iron-mediated downregulation of TfR1 mRNA levels by reverse
transcriptase PCR (RT-PCR) (Fig. 6b). Fenofibrate treatment in
mouse primary RPE cells also resulted in a similar normalization of
iron-mediated increase in Ferritin levels (Supplementary Fig. 2a)
and decrease in TfR1 levels (Supplementary Fig. 2b). We confirmed
further by direct intracellular iron estimation using inductively
coupled plasma-mass spectrometry (ICP-MS) (Fig. 6c) and by
FeRhonox-1 staining for labile iron in ARPE19 cells (Fig. 6d). In
addition, fenofibrate treated cells showed lower ROS generation
compared to the cells treated with FAC (Fig. 6e). Fenofibrate
significantly inhibited the ferrozine-Fe2+ complex formation
Fig. 3 Iron accumulation and enhanced Wnt signaling in the rd1 mouse model of Retinitis Pigmentosa. a TfR1, Heavy (H-) chain ferritin,
light (L-) chain ferritin, and b active β-catenin protein levels were determined by immunoblotting in WT and rd1 mouse at postnatal day 16.
Blots cropped from different parts of the same gel or from different gels are separated by white space in a and b. c mRNA expression of Wnt
downstream target genes Axin2, cMYC, CCND in WT, and rd1 mice retina at P16. d Representative images of retinal sections from P16 WT and
rd1 mice stained for labile iron using FeRhoNox-1 fluorescent imaging probe. e 4-Hydroxynonenal staining in WT and rd1 mouse retina at P16.
Scale bar is 100 μm for all the panels in d and e. Data presented as mean ± SE of three independent experiments; n= 3 mice per group; *p <
0.05; **p < 0.001.
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(Fig. 6f), indicating that fenofibrate binds to Fe2+ and chelates iron
in turn leading to reduction in intracellular iron levels. We found
that the active form of fenofibrate, fenofibric acid, also inhibited
the ferrozine-Fe2+ complex significantly albeit with a lower
potency than fenofibrate (Supplementary Fig. 3).
Fenofibrate downregulates FAC-induced RAS signaling
Retina expresses all the components of the RAS. We investigated
the effect of fenofibrate on FAC-induced RAS activation in ARPE19
cells. FAC-treated cells showed increased expression of ANG II/III
and Renin, which were significantly prevented by fenofibrate
treatment in RPE cells (Fig. 7a). Fenofibrate also normalized the
iron and LiCl-mediated upregulation of AGT and AT1R (Fig. 7b-e),
the other RAS genes that are downstream targets of Wnt
signaling. These results suggest that fenofibrate prevents the
RAS activation by inhibiting Wnt signaling in RPE cells as shown in
Fig. 8.
DISCUSSION
Wnt signaling pathway is an important regulator of retinal
development at various stages including retinal stem cell
maintenance, ciliary body formation, cornea and lens formation,
retinal field establishment, and retinal vasculogenesis40. Hence,
mutation in many components of the Wnt signaling such as Fzd-
441, LRP5/642, Norrin43, or APC44 result in defective retinal
vasculogenesis leading to compensatory neovascularization,
vascular leakage, retinopathy of prematurity, retinal detachment,
or in certain cases retinal coloboma. On the contrary, aberrant
activation and nuclear localization of β-catenin has been
demonstrated during ocular pathologies like DR45,46, AMD47–49,
proliferative retinopathy50, and laser induced choroidal neovascu-
larization51, and blocking of Wnt signaling resulted in anti-
inflammatory and anti-angiogenic effects52–54. There is an
emerging body of evidence implicating iron accumulation in
aging4,5 and retinal degenerative diseases6–15, but whether this
involves Wnt signaling has not been studied. Here, we demon-
strate that iron overload activates retinal canonical Wnt signaling
both in vitro and in vivo. We observed that in the retina, iron
inhibits GSK-3β, upregulates LRP6 and β-catenin levels, increasing
the translocation of active β-catenin to the nucleus and
upregulating β-catenin downstream target genes of the RAS,
which are known to be regulated by TCF binding to their
promoter17. Our results further establish that iron-mediated
upregulation of Wnt/β-catenin signaling is dependent on oxida-
tive stress as treatment with antioxidant NAC or iron chelator DFP
abrogated the iron-mediated Wnt activation.
Iron overload is associated with the pathophysiology of several
diseases including cancer2. Similarly, Wnt signaling is a major
oncogenic signaling pathway underlying carcinogenesis in many
tissues55. Under normal conditions, iron has been found to either
not alter or downregulate Wnt/β-catenin signaling in colon and
liver respectively56,57. On the other hand, our present study
showing upregulation of canonical Wnt signaling by iron in the
retina of WT mouse with functional APC and β-catenin indicates a
strong tissue-dependent differential regulation of Wnt signaling
by iron. Two independent groups have shown that multiple iron
chelators inhibit Wnt/β-catenin signaling and block cancer cell
growth38,39. In addition, lipid peroxidation product, 4-HNE
treatment to RPE cells and retinal endothelial cells, has been
reported to increase the levels of phosphorylated and total LRP6,
β-catenin, and TCF/β-catenin downstream genes58. Thus, our
present finding that treatment with antioxidant NAC or iron
chelator DFP abrogates the iron-mediated LRP6 and Wnt
activation implicates iron-catalyzed 4-hydroxenonenal as at least
partly responsible for the iron-induced Wnt activation in the
retina. However, future studies will be aimed at discerning the
differential mechanisms involved in the tissue-dependent regula-
tion of Wnt/β-catenin signaling by iron.
Oxidative stress is considered as one of the possible mechan-
isms for the progressive death of cones and rods in RP33.
Importantly, use of antioxidants has been found to reduce rod cell
Fig. 4 Iron induced Wnt signaling activation is mediated by oxidative stress. a, b Expression of Src collagen homolog (SHC1), an indicator
of redox imbalance and oxidative stress, in the ARPE19 cells treated with FAC for 24 h and in mice treated with intraperitoneal iron dextran for
8 weeks. c ARPE19 cells when treated with FAC for 24 h along with antioxidant N-acetyl cysteine (NAC) or iron chelator deferiprone (DFP)
normalized active β-catenin and LRP6 levels in western blotting. d Cytosolic and nuclear fractions were separated and the expression of active
β-catenin was determined by western blotting. β-Actin and HDAC1 were used as loading controls for cytosolic and nuclear fractions
respectively. Blots cropped from different parts of the same gel or from different gels are separated by white space. Data presented as mean ±
SE of three independent experiments. *p < 0.05; **p < 0.001.
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death in the rd1 and rd10 mouse models of RP33. In addition, iron-
chelating drugs delayed retinal degeneration in rd10 mouse
model of RP34. Interestingly, a clinical case reported recently of a
35-year-old patient with a missed iron foreign body in left eye for
7 years, presenting with a pseudo-RP-like fundus59, indicates a
causative role for iron in developing RP-like phenotype. We show
that iron accumulation in rd1 mice of different ages is associated
with enhanced activation of canonical Wnt signaling in the retina
providing a possible mechanism by which iron regulates RP
pathogenesis. Hence, iron chelation therapy as a potential
preventive strategy for RP warrants further investigation. Also,
how a mutation in beta subunit of the cGMP phosphodiesterase
gene in rd1 mice leads to iron accumulation in the retina before
cell death begins is a critical question that needs further
exploration.
PPARα downregulation has been implicated in DR29 and AMD60,
which may be responsible for the overactivation of Wnt
signaling30, thereby contributing to the disease progression.
PPARα activation by its agonist fenofibrate has recently been
shown to attenuate several mediators of vascular damage
including inflammation, endothelial dysfunction, and angiogen-
esis during DR and AMD27,28,60–66. In the present study, we found
that treatment with fenofibrate prevented iron-induced dysregu-
lation of Wnt signaling in both human and mouse RPE cells.
Previous reports on small molecule drugs with iron binding and
chelating activity abrogating the Wnt signaling and inhibiting the
cancer cell growth38,39 led us to hypothesize that fenofibrate acts
as an iron chelator. We found that fenofibrate reduced
intracellular labile iron and ROS levels. Further, our ICP-MS and
Ferrozine iron chelation assay strongly demonstrated that
fenofibrate treated cells have significantly lower levels of
intracellular iron by chelating it. Although we found only one
clinical report on fenofibrate inducing anemia67, interestingly, the
EFECTL Study (Effect of Fenofibrate and Ezetimibe Combination
Treatment on Lipid Study), a three-arm parallel-group open-label
randomized trial, reported that 52 patients undergoing fenofibrate
monotherapy alone had a significant reduction in the red blood
cell count and hemoglobin starting from 4 weeks after treatment
was initiated until 52 weeks for the entire duration of the study68.
Our present finding that fenofibrate is an iron chelator provides a
plausible explanation for the results seen in EFECTL trial. In
summary, our study demonstrates that iron accumulation in the
retina inhibits GSK-3β and activates LRP6 and β-catenin signaling
in an oxidative stress-dependent mechanism. In addition, we
report a previously unidentified pharmacological effect of
fenofibrate as an iron chelator reducing intracellular iron
accumulation. This work has significant translational potential as
fenofibrate could be an attractive therapeutic drug for the
treatment of many chronic diseases associated with iron overload.
METHODS
Animals
C57BL/6J mice, Axin2LacZ/+ mice, and C57BL/6Jrd1/le (rd1 mice) breeders
were purchased from Jackson Laboratory (Bar Harbor, ME). All the mice
were housed at the animal facility of Saint Louis University School of
Medicine. Gender, age and weight matched animals were randomly
divided into different groups as indicated in the results. All procedures
involving mice were approved by the Saint Louis University Institutional
Committee on Animal Use for Research and Education and were
Fig. 5 PPARα agonist fenofibrate prevents iron-induced Wnt signaling activation in ARPE19 cells. ARPE19 cells were treated with 50 and
100 µM of Fenofibrate (Feno) along with 100 µg/ml FAC for 24 h, and the protein expression of a active and T-β-catenin, b p-LRP6 and p-GSK-
3β were determined by immunoblotting. β-Actin was used as a loading control. c Cytosolic and nuclear proteins were isolated after the cells
were treated with fenofibrate in the presence of FAC for 24 h and the expression of active β-catenin was determined by western blotting.
d Active β-catenin, total β-catenin, and SHC1 protein levels were assessed by western blotting in mouse primary RPE cells treated with FAC
and fenofibrate. Blots cropped from different parts of the same gel or from different gels are separated by white space. Data presented as
mean ± SE of three independent experiments. *p < 0.05; **p < 0.001.
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performed in accordance with the Association for Research in Vision and
Ophthalmology Statement for the Use of Animals in Ophthalmic and
Vision Research.
Intravitreal and intraperitoneal injections
Considering the toxicity of FAC to the retina, holo-transferrin was injected
intravitreally in mice to simulate iron overload. Briefly, animals were
anesthetized with 1 : 1 mix of ketamine (8mg/ml) and xylazine (1.2 mg/ml).
Pupils were dilated with 1% atropine sulfate ophthalmic solution. Animals
were injected with 1 μL of 2.4 mM holo-transferrin (Holo-Tf) or 1 μL of
2.4 mM apo-Tf as control. Twenty-four hours post injection, mice were
killed and retinas were collected. For systemic iron overload, mice were
administered with iron-dextran (1 g/kg body weight) intraperitoneally once
a week for a duration of 8 weeks. PBS was administered intraperitoneally to
the control group.
Cell culture
The human RPE cell line, ARPE19 was procured from American Type
Culture Collection (Manassas, VA) and maintained in 1 : 1 Dulbecco’s
modified Eagle’s medium/F12 (DMEM/F12, Invitrogen, Gibco Corp., Grand
Island, NY) supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, UT) and 100 IU/ml penicillin and 100 μg/ml streptomycin (Invitro-
gen, Carlsbad, CA, USA) at 37 °C in a humidified air chamber with 5% CO2.
For biochemical experiments, cells were seeded in a six-well plate (unless
otherwise mentioned) and were utilized after reaching 90% confluence
followed by a 5–6 h serum starvation before any treatment was done.
Mouse primary RPE cell cultures
Three-week-old C57BL/6 pups were used to isolate primary RPE cells as
described previously7. Cells were grown in 1 : 1 DMEM/F12 (Invitrogen,
Gibco Corp., Grand Island, NY) supplemented with 25% FBS (Hyclone,
Logan, UT) and 5% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA)
at 37 °C cell culture incubator with 5% CO2. Purity of the cultures was
verified as described previously by immunodetection of RPE65, a known
marker for RPE cells 7.
RNA isolation, cDNA synthesis, and RT-PCR
Cells were treated with the experimental conditions and total RNA was
extracted using Trizol (Invitrogen, USA) and the quantity of the extracted
RNA was assessed by measuring the absorbance at 260 nm. RNA (500 ng)
was reverse transcribed to synthesize the cDNA using iScript™ cDNA
Synthesis Kit (Bio-Rad, USA) according to the manufacturer’s protocol.
Then, cDNA was diluted (1 : 5) and utilized to assess the gene expression
by ABI Quant Studio3 real-time PCR system using iTaq™ Universal SYBR®
Green Supermix (Bio-Rad, USA). The list and sequence of specific primers
used are provided in Supplementary Table 1.
Immunoblotting
Protein was extracted from the cells and the tissues using a lysis buffer
(50mM Tris, 150 mM NaCl, 10 mM EDTA) supplemented with protease
inhibitors (1 μg/ml aprotinin, 1 μg/ml pepstatin, 1 μg/ml leupeptin, 1 mM
phenylmethylsulfonyl fluoride, 1 μg/ml trypsin inhibitor) and 1% NP-40.
The concentration of the protein was estimated by bicinchoninic acid
assay (Thermo Fisher Scientific, Waltham, MA). Protein (20 µg) was
subjected to SDS-polyacrylamide gel electrophoresis and transferred onto
the nitrocellulose membrane. The membrane was then blocked for 1 h
with 3% bovine serum albumin (fatty acid free) and incubated with the
primary antibodies overnight at 4 °C. Then, the blots were washed and
incubated with secondary antibodies for 90min at room temperature (RT).
Blottings were again washed and the proteins were visualized using
enhanced chemiluminescence western blotting detection system (Thermo
Fisher Scientific, Waltham, MA). Antibody sources and dilutions used are
Fig. 6 Fenofibrate prevents iron-induced Wnt signaling activation by chelating iron. a TfR1 and L&H ferritin protein levels in ARPE19 cells
treated with FAC and fenofibrate by western blotting. bmRNA expression of TfR1 was determined by real-time PCR. c Intracellular iron content
were quantified by ICP-MS. d Cells were stained for labile iron (Fe2+) using FeRhoNox-1 fluorescent imaging probe. e ROS generation was
monitored by CM-H2DCFDA staining and quantified. f Iron-chelating activity of fenofibrate was assessed based on its ability to interfere with
the formation of ferrozine-Fe2+ complex when treated along with FeCl2. Iron chelator deferiprone (DFP) was used as a positive control. Data
presented as mean ± SE of three independent experiments. *p < 0.05; **p < 0.001, ***p < 0.0001.
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listed in Supplementary Table 2. All blots or gels were derived from the
same experiment and were processed in parallel.
Nuclear and cytosolic protein isolation
Cells with or without treatment were washed with PBS at 4 °C and the
cytosolic and nuclear fractions of cells lysates were purified using the NE-
PER™ nuclear and cytoplasmic extraction reagent (Thermo Fisher, Waltham,
MA) following the manufacturer’s guidelines.
Luciferase assay
Wnt activity was measured by using the TCF/LEF Reporter Kit (BPS
Bioscience, USA). Briefly, cells were seeded at a density of 10,000 cells per
well in a 96-well plate, transfected with either negative control or reporter
Fig. 7 Fenofibrate downregulates FAC-induced RAS signaling. a Protein levels of ANG II/III and renin were quantified by western blot in RPE
cells treated with fenofibrate in the presence of 100 µg/ml FAC for 24 h. b, c mRNA expression of angiotensinogen was monitored by RT-PCR.
d, emRNA expression of ATR1 was determined by RT-PCR. LiCl treatment was done as a positive control. Data presented as mean ± SE of three
independent experiments. *p < 0.05.
Fig. 8 Schematic illustration. A schematic of the signaling pathways showing fenofibrate preventing iron-induced activation of oxidative
stress, Wnt/β-catenin and renin–angiotensin system signaling.
A. Mandala et al.
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plasmid as mentioned in the kit. Wnt pathway activity was detected using
the Dual Luciferase Assay System, normalized with Renilla, and calculated
according to the TCF/LEF Reporter Kit data sheet.
Histological detection of labile iron
Eyecups were fixed in 4% paraformaldehyde and embedded in OCT
(Optimal Cutting Temperature) compound for cryosectioning as previously
described69. Labile iron (Fe2+) in retinal sections were detected using
FeRhoNox-1 fluorescent imaging probe as mentioned in our recent
publications10,70. RhoNox-1 was dissolved in dimethyl sulfoxide to a final
concentration of 5 μM, added to the retinal sections, and incubated for
30min at 37 °C in a dark chamber. The sections were then counterstained
with Hoechst nuclear stain and examined by laser-scanning confocal
microscopy (Carl Zeiss, Oberkochen, Germany).
Immunofluorescence analysis
Retinal sections were fixed, blocked with 1× power block and incubated
overnight at 4 °C with rabbit anti-HNE. Negative control sections were
incubated without the primary antibody. Sections were rinsed and
incubated for 1 h with goat anti-rabbit IgG coupled to Alexa Fluor 488.
Coverslips were mounted after staining with Hoechst nuclear stain and
sections were observed using laser-scanning confocal microscopy.
Immunohistochemistry studies were repeated twice, and the results from
these two experiments were similar.
β-Galactosidase staining
β-Galactosidase reporter gene staining kit (Millipore Sigma, St. Louis, USA)
was used to stain retinal sections from Axin2LacZ/+ mice according to the
manufacturer’s protocol.
Measurement of intracellular ROS production
Intracellular ROS generation was monitored by CM-H2DCFDA staining
according to the manufacturer’s protocol (Molecular Probes, Thermo
Fisher, Waltham, MA).
Inductively coupled plasma-mass spectrometry
Intracellular iron levels were estimated by using ICP-MS. ARPE19 cells were
cultured in T-75 tissue culture flask and treated according to the
experimental conditions. At the end of the treatment, the flask was rinsed
with PBS for three times and cells were detached by 0.25% trypsin-EDTA.
After centrifugation, the cells were suspended in 1ml PBS and counted.
Then the cells were centrifuged at 16,100 × g for 10 min at 4 °C and the
resultant pellet was stored at −80 °C until ICP-MS analysis. On the day of
analysis, frozen cell pellets were thawed and thermally digested in 1ml
nitric acid (HNO3) using Mars 6 Microwave Digestion System (CEM
Corporation). Digested samples were diluted for mass spectrometric
analysis and total iron content of the samples was estimated using
PerkinElmer NexION 2000 ICP-MS in Washington University, St. Louis. A
standard calibration curve was performed prior to sample analysis. The
total iron content per cell was calculated, accounting for the number of
cells present, as well as dilution factors, as the mean value of three
individual experiments groups.
Iron chelation assay
The chelation of ferrous iron by fenofibrate was determined by method
described previously71. Briefly, FeCl2 (50 µl, 2 mM) was mixed with different
concentrations of fenofibrate. Then, 200 µl of 5 mM ferrozine solution was
added to initiate the reaction followed by vigorous shaking. After
incubating the reaction for 10min at RT, the absorbance of the solution
was recorded at 562 nm. The percentage inhibition of the ferrozine-Fe2+
complex formation was calculated as (A0− As/As) × 100. Here, A0 and As
represents the absorbance of the control and fenofibrate/fenofibric acid/
DFP, respectively.
Statistical analysis
Data are presented as mean ± SEM. The fold change for bar graphs were
calculated by normalizing the sample values with the respective control
values. Statistical significance was determined with the Student’s t-test. All
the experiments were performed in triplicates. The values of p < 0.05 were
considered significant 48.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The datasets generated and analyzed during the current study are available from the
corresponding author on reasonable request.
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